205 related articles for article (PubMed ID: 29652599)
1. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
[TBL] [Abstract][Full Text] [Related]
2. Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers.
Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
Thyroid; 2018 Apr; 28(4):445-453. PubMed ID: 29652597
[TBL] [Abstract][Full Text] [Related]
3. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
4. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
[TBL] [Abstract][Full Text] [Related]
5. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.
Bilen MA; Patel A; Hess KR; Munoz J; Busaidy NL; Wheler JJ; Janku F; Falchook GS; Hong DS; Meric-Bernstam F; Habra MA; Naing A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):167-71. PubMed ID: 27286994
[TBL] [Abstract][Full Text] [Related]
6. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
7. Frequency and Severity of Hypothyroidism During TKI Therapy in the Pediatric and Young Adult Population.
Segev N; Arora S; Khoury J; Yayah Jones NH; Chuang J
J Pediatr Hematol Oncol; 2022 Oct; 44(7):e964-e967. PubMed ID: 35973039
[TBL] [Abstract][Full Text] [Related]
8. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
[TBL] [Abstract][Full Text] [Related]
9. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
[TBL] [Abstract][Full Text] [Related]
10. Clinical Course of Early Postoperative Hypothyroidism Following Thyroid Lobectomy in Pediatrics.
Baran JA; Bauer AJ; Halada S; Mostoufi-Moab S; Isaza A; Robbins S; Franco AT; Adzick NS; Patel T; Kazahaya K
Thyroid; 2021 Dec; 31(12):1786-1793. PubMed ID: 34714171
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.
Illouz F; Laboureau-Soares S; Dubois S; Rohmer V; Rodien P
Eur J Endocrinol; 2009 Mar; 160(3):331-6. PubMed ID: 19103722
[TBL] [Abstract][Full Text] [Related]
12. Association between serum free thyroxine concentration and atrial fibrillation.
Gammage MD; Parle JV; Holder RL; Roberts LM; Hobbs FD; Wilson S; Sheppard MC; Franklyn JA
Arch Intern Med; 2007 May; 167(9):928-34. PubMed ID: 17502534
[TBL] [Abstract][Full Text] [Related]
13. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
[No Abstract] [Full Text] [Related]
14. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
Drui D; Illouz F; Do Cao C; Caron P
Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
[TBL] [Abstract][Full Text] [Related]
15. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
16. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients.
Drechsler C; Schneider A; Gutjahr-Lengsfeld L; Kroiss M; Carrero JJ; Krane V; Allolio B; Wanner C; Fassnacht M
Am J Kidney Dis; 2014 Jun; 63(6):988-96. PubMed ID: 24315768
[TBL] [Abstract][Full Text] [Related]
17. Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and Fibrosis.
Kim D; Kim W; Joo SK; Bae JM; Kim JH; Ahmed A
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):123-131.e1. PubMed ID: 28823829
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
[TBL] [Abstract][Full Text] [Related]
19. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.
Rodondi N; Newman AB; Vittinghoff E; de Rekeneire N; Satterfield S; Harris TB; Bauer DC
Arch Intern Med; 2005 Nov; 165(21):2460-6. PubMed ID: 16314541
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-induced Thyroid Dysfunction Is Associated with Higher Body Mass Index.
Pollack R; Ashash A; Cahn A; Rottenberg Y; Stern H; Dresner-Pollak R
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32668461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
